COMMUNIQUÉS West-GlobeNewswire

Cannabix Technologies Announces Commercial Launch of Marijuana Breath Test (MBT)
16/03/2026
VANCOUVER, British Columbia, March 16, 2026 (GLOBE NEWSWIRE) -- Cannabix Technologies Inc. (CSE: BLO) (OTCID: BLOZF) (Frankfurt: 8CT) (the “Company” or “Cannabix”) is pleased to announce the commencement of its [...]
Amlogenyx Announces Positive Preclinical Data on AM805, a Potent Amyloid-Degrading Protease for the Treatment of Alzheimer’s Disease
16/03/2026
Novel and potent catalytic approach that directly clears amyloid on the inside of neurons as well as reduces amyloid plaques with the potential to be superior to monoclonal antibodies and restore neuronal function while [...]
TOMI Environmental Solutions Expands Footprint Across Canada
16/03/2026
Strategic Growth Driven by SteraMist iHP Technology Placements in Premier Healthcare and Pathogen Research Facilities FREDERICK, Md., March 16, 2026 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc.® (“TOMI”) ( [...]
A Race Against Blindness Announces Spring 2026 Luxury Vehicle Fundraiser in Partnership with Foundation Fighting Blindness to Advance Pediatric Inherited Retinal Disease Research
16/03/2026
SCOTTSDALE, Ariz., March 16, 2026 (GLOBE NEWSWIRE) -- A Race Against Blindness (RAB) today announced the launch of its Spring 2026 national fundraiser, Two Winners, One Drive for Vision Research , in strategic [...]
SciSparc: NeuroThera Labs- Clearmind Medicine Collaboration Leads to Patent Application for Depression Therapy
16/03/2026
TEL AVIV, Israel, March 16, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), today announced that NeuroThera Labs Inc. (TSXV: NTLX) ("NeuroThera"), a clinical-stage pharmaceutical company [...]
Novonesis issues EUR 1.7 billion in bonds to refinance bridge facility
16/03/2026
COPENHAGEN, Denmark – March 16, 2026 . Novonesis has completed a EUR 1.7 billion bond issuance, with significant interest from a broad group of investors. The transaction was primarily undertaken to refinance the bridge [...]
Milestone Pharmaceuticals to Present Data on CARDAMYST™ (etripamil) Nasal Spray at the 2026 American College of Cardiology Annual Scientific Session
16/03/2026
MONTREAL and CHARLOTTE, N.C., March 16, 2026 (GLOBE NEWSWIRE) -- Milestone ® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular [...]
Fennec Pharmaceuticals Announces Settlement Agreement Resolving PEDMARK Patent Litigation
16/03/2026
RESEARCH TRIANGLE PARK, N.C., March 16, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company, today announces that it has entered into an agreement with Cipla [...]
Outlook Therapeutics Announces New $18.4 Million Non-Convertible Note Financing and Amendment to Existing Convertible Note
16/03/2026
ISELIN, N.J., March 16, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, [...]
Herantis Pharma to present HER-096 Phase 1b data at International Conference on Alzheimer’s & Parkinson’s Diseases
16/03/2026
Espoo, Finland, March 16, 2026: Herantis Pharma Plc ("Herantis"), a clinical-stage company developing disease-modifying therapies to stop the progression of Parkinson’s disease, announces that its Chief Scientific [...]
George Medicines extends global commercialization of GMRx2 into Australia and New Zealand with Arrotex licensing agreement
16/03/2026
Arrotex gains exclusive rights in Australia and New Zealand to innovative single pill combination of three hypertension medicines, including two doses that are lower than those currently available in single pill [...]
Daré Bioscience Receives NIH Funding Award Notice to Advance DARE-PTB1, its Novel Intravaginal Ring for Prevention of Preterm Birth
16/03/2026
• Extends the budget period for the ~$2M total NIH grant funding award for DARE-PTB1 through November 2026 • DARE-PTB1 targets preterm birth, for which there are no FDA-approved treatment options • Award reflects Daré's [...]
Aprea Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update
16/03/2026
Early clinical proof-of-concept for WEE1 inhibitor APR-1051 in the ongoing ACESOT-1051 trial with two partial responders at first scan in endometrial cancer patients with PPP2R1A mutation Clinical team strengthened with [...]
Extendicare Announces March 2026 Dividend of C$0.0441 per Share
16/03/2026
MARKHAM, Ontario, March 16, 2026 (GLOBE NEWSWIRE) -- Extendicare Inc. (“Extendicare” or the “Company”) (TSX: EXE) announced that it has declared a cash dividend of C$0.0441 per common share of the Company for the month [...]
HCW Biologics Announces Positive Research Results for CAR-T Cell Therapy Manufactured Utilizing Its Commercial-Ready Proprietary Compound, HCW9206, Published in Science Advances
16/03/2026
Commercialization ready compound supports a new method of generating highly functional human CAR-T cells for treating infectious diseases and cancer In experimental models, human CAR-T cells manufactured using HCW9206 [...]
Cogent Biosciences Announces FDA Acceptance of New Drug Application for Bezuclastinib in Patients with NonAdvanced Systemic Mastocytosis (NonAdvSM)
16/03/2026
NDA based on positive clinical results from the SUMMIT pivotal trial in which bezuclastinib demonstrated clear clinical benefit across all symptom domains WALTHAM, Mass. and BOULDER, Colo., March 16, 2026 (GLOBE [...]
vTv Therapeutics to Participate in the 38th Annual ROTH Conference
16/03/2026
HIGH POINT, N.C., March 16, 2026 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin , a novel, potential first-in-class oral [...]
New Two-Year Data from Pivotal ApproaCH Trial Showing Durable Benefits of TransCon® CNP (Navepegritide) in Children with Achondroplasia Shared at ACMG 2026
16/03/2026
COPENHAGEN, Denmark, March 16, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced new data from its pivotal ApproaCH Trial showing that children with achondroplasia treated with once-weekly [...]
Recludix Pharma Promotes Executive Leaders Following Recent Corporate Accomplishments
16/03/2026
– Ajay Nirula, M.D., Ph.D., will now also serve as president, in addition to his role as head of research and development - Catherine Bovenizer, C.P.A., has been named chief financial officer, following her tenure as [...]

Pages